Overview

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Treatments:
Atezolizumab